Send the following on WhatsApp
Continue to ChatBiocon’s drug Itolizumab gets DCGI Nod for treatment of moderate to severe COVID patients - Republic World - Republic World https://www.indiafinancenews.com/biocons-drug-itolizumab-gets-dcgi-nod-for-treatment-of-moderate-to-severe-covid-patients-republic-world-republic-world/